WebRenaissance Capital — Oncology biotech Acrivon Therapeutics prices IPO at $12.50, well below the range Find More Contacts for Acrivon Therapeutics Peter Blume-Jensen CEO, Founder, President Executive Management 1 email found View contacts for Acrivon Therapeutics to access new leads and connect with decision-makers. View All Contacts … WebMar 26, 2024 · ACRV, a recent IPO, has a market cap of $273mn, a stock price of $13, and a cash reserve of $170mn. There are financial statements from September 2024 - here - where cash shown is some $77mn.
Cancer biotech Acrivon files for IPO - Boston Business Journal
WebNov 15, 2024 · Acrivon Therapeutics, a Phase 2 biotech developing proteomics-based precision oncology therapies, raised $94 million by offering 7.6 million shares at $12.50, well below the range of $16 to $18. The company offered 1.7 million more shares than anticipated, and prior to pricing, it had disclosed insider indications on 88% of shares in … WebNov 15, 2024 · In addition to the shares sold in the initial public offering, Acrivon announced a concurrent sale of 400,000 shares of common stock at the public offering price per … go math 8th grade hrw
ACRV Acrivon Therapeutics Inc. Stock Overview (U.S.: Nasdaq) …
WebNov 3, 2024 · Acrivon's IPO Details ACRV intends to sell 5.9 million shares of common stock at a proposed midpoint price of $17.00 per share for gross proceeds of … WebNov 3, 2024 · Acrivon Therapeutics (ACRV proposed), a cancer biotech, filed terms – 5.9 million shares at $16.00 to $18.00 – early today (Thursday, Nov. 3, 2024) and landed on next week’s IPO Calendar. The deal, which will raise $100.3 million if priced at the $17.00 mid-point, launched today as well. WebAcrivon Therapeutics Inc (NASDAQ:ACRV) Intrinsic Valuation. Check if ACRV is overvalued or undervalued under the bear, base, and bull scenarios of the company's future. healthcare writing topics